Banco Santander-Chile reports Q2 results on July 29 with analysts pulling in opposite directions — a rare three-way split between a bellwether Sell, a fresh Buy upgrade, and a cautious Neutral, all in the past five weeks.
The most striking tension in the analyst community is between Goldman Sachs and JPMorgan. Goldman's Tito Labarta raised his price target from $29 to $33 on July 16, but kept his Sell rating — a signal that the stock has re-rated faster than his conviction allows. JPMorgan upgraded to Overweight back in March with a $40 target, implying roughly 20% upside from the current $33.47. Citigroup flipped to Buy in late June without disclosing a target, adding a third constructive voice. The mean consensus target sits at $34.25 — only marginally above the current price — which reflects the Goldman anchor dragging on an otherwise improving picture. UBS sits at Neutral with a $31 target, meaning two of the five visible names are effectively below the market.
The bull case rests on valuation and earnings momentum. At 11.4x trailing earnings and 2.6x book, BSAC is not expensively priced for a franchise that has beaten estimates consistently — the stock ranks in the 82nd percentile on EPS surprise history. Forward earnings estimates have been revised sharply higher, with 12-month EPS growth projections running well above year-ago levels. Bears point to macro sensitivity: BSAC's results track Chilean interest rate policy and peso dynamics closely, and the 30-day EPS forward momentum rank sits in only the 22nd percentile, suggesting the pace of upward revisions may be cooling. The stock's one-month gain of 3.8% to $33.47 has brought it close to Goldman's ceiling target, which may explain why the Sell persists even as the target moved up.
Positioning in the lending market gives no added signal in either direction — borrow is essentially unconstricted. Availability runs near 957%, meaning there are roughly ten shares available to borrow for every one currently shorted, and cost to borrow has eased sharply from above 1% in early July to around 0.55%. Short interest has drifted down roughly 4% over the past month. Options activity is similarly muted, with the put/call ratio running near zero for most of the past 30 days, indicating almost no hedging demand into the print. Past earnings reactions have been asymmetric: the two most recent prints in late April produced day-one moves of -2.4% and -3.9%, while the July 10 announcement drew only a 0.4% move. The Q2 release will test whether the JPMorgan bull thesis — that improving Chilean credit conditions and EPS inflection justify a premium re-rating — can overcome the ceiling Goldman has effectively placed on the stock.
See the live data behind this article on ORTEX.
Open BSAC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
